Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$8.73 – $9.86
88% from low
Borrow rate
4.21%
Moderate
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $9.1M | $11.4M | −$8.8M | $36.8M | −$20.8M | −$3.1M | $15.8M | $10.5M |
| Cost of revenue | $0 | $0 | $0 | $24.8M | $0 | $0 | $3.6M | $1.9M |
| Gross profit | $9.1M | $11.4M | −$8.8M | $12.0M | −$20.8M | $11.0M | $12.2M | $8.6M |
| Gross margin | 100.0% | 100.0% | 100.0% | 32.5% | 100.0% | -351.6% | 77.2% | 81.9% |
| R&D | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating income | $10.8M | $10.9M | $10.4M | $10.0M | $9.8M | $9.4M | $11.9M | −$5.6M |
| EBITDA | $10.8M | $0 | $0 | $0 | $0 | $0 | $11.9M | −$5.6M |
| Net income | $8.8M | $11.2M | −$9.0M | $36.6M | −$21.0M | −$3.4M | $11.9M | −$8.7M |
| Net margin | 97.5% | 98.2% | 102.5% | 99.4% | 101.3% | 107.4% | 75.6% | -82.7% |
| EPS (diluted) | 0.66 | 0.82 | -0.66 | 2.72 | -1.56 | -0.25 | 0.89 | -0.65 |
Annual figures · source: Financial Modeling Prep
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| BTABlackRock Long-Term Municipal Advantage Trust | $9.72 | -0.10% | $131M | — |
| ARHVXAmerican Century One Choice 2065 Inv | $14.94 | +0.40% | $151M | — |
| BKNBlackRock Investment Quality Municipal Trust Inc. | $11.54 | +0.00% | $199M | — |
| DMOWestern Asset Mortgage Opportunity Fund Inc | $10.77 | +0.51% | $123M | — |
| IAFAbrdn Australia Equity Fund Inc |
No one on the platform currently holds BTA.
No tracked institution reports a position in BTA as of their last filing.
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-02-06 | $0.0495 | 2026-03-02 |
| 2026-01-20 | $0.0495 | 2026-02-02 |
| 2025-12-22 | $0.0495 | 2025-12-31 |
| 2025-11-14 | $0.0495 | 2025-12-01 |
| 2025-10-15 | $0.0495 | 2025-11-03 |
| 2025-09-15 | $0.0495 | 2025-10-01 |
| 2025-08-15 | $0.0495 | 2025-09-02 |
| 2025-07-15 | $0.0495 | 2025-07-31 |
| 2025-06-13 | $0.0495 | 2025-07-01 |
| 2025-05-15 | $0.0495 | 2025-06-02 |
No one on the platform has traded BTA yet.
| $12.29 |
| -0.77% |
| $118M |
| — |
| POIIXPolen International Growth Institutional | $14.78 | +1.09% | $87M | — |
| POIRXPolen International Growth Investor | $14.55 | +1.11% | $87M | — |
Source: Financial Modeling Prep · peers by sector/industry
| 2025-04-15 |
| $0.0495 |
| 2025-05-01 |
| 2025-03-14 | $0.0495 | 2025-04-01 |
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
$BTA give me $10 b4 market close. Or else 12/08/25 is a brutal Bullish SH here. Is gonna wanna be loud 📢 📢 📢 📢 ER. Coming shortly soon
View on StockTwits ↗$ACON People, did you see the fall of $BTA? It will come to $ACON accordingly
View on StockTwits ↗I found you an Overbought RSI (Relative Strength Index) on the daily chart of BlackRock Long-Term Municipal Advantage Trust. Is that bullish or bearish? $BTA #RsiOverbought #NYSE
View on StockTwits ↗$BTA new insider buying: 10 shares. http://insiderbuyingselling.com/?t=BTA
View on StockTwits ↗I found you an Oversold RSI (Relative Strength Index) on the daily chart of BlackRock Long-Term Municipal Advantage Trust. Is that bullish or bearish? $BTA #RsiOversold #NYSE
View on StockTwits ↗I found you an Overbought RSI (Relative Strength Index) on the daily chart of BlackRock Long-Term Municipal Advantage Trust. Is that bullish or bearish? $BTA #RsiOverbought #NYSE
View on StockTwits ↗I found you an Overbought RSI (Relative Strength Index) on the daily chart of BlackRock Long-Term Municipal Advantage Trust. Is that bullish or bearish? $BTA #BTA #nyse #tradingsignals #technicalanalysis
View on StockTwits ↗$BTA looking forward to not paying taxes so adding this to my taxable brokerage account 3 of 5
View on StockTwits ↗$BTA Reg Statement S12-13: "We also intend to propose that we should not assess efficacy in this trial since we believe there are no well-defined and validated measures of efficacy for the at-home setting of acute agitation as measured by the caregiver, notwithstanding that the FDA stated that we should collect such efficacy data at our October 2023 meeting. We believe that the efficacy of BXCL501 for the treatment of agitation in dementia patients has already been established in our Phase 3 study (BXCL501-303) and is further supported by additional efficacy data from BXCL501-103, our Phase 2 study, and from the evaluation of BXCL501 in the treatment of agitation in schizophrenia (BXCL501-301) and bipolar disorders (BXCL501-302). However, the FDA may not agree with our proposed trial design to evaluate both the safety and efficacy of BXCL501 for the acute treatment of agitation associated with dementia due to probable Alzheimer’s disease in an at-home setting.
View on StockTwits ↗$BTA I think @kror74 should male a statement! Lots of people trusted him. You need to own it @kror74 . Don't run. Own it.
View on StockTwits ↗$BTAI: Kessler Topaz Meltzer & Check, LLP Notification: Deadline Reminder for BioXcel Therapeutics, Inc. ($BTA ... https://www.chartmill.com/stock/quote/BTAI/news?utm_source=stocktwits&utm_medium=pressRelease&utm_content=BTAI&utm_campaign=social_tracking
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.